Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
/Free Sign Up
 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Roche Holding AG (RO)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create a new watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
365.20 +1.60    +0.44%
11/06 - Closed. Currency in CHF ( Disclaimer )
Type:  Equity
Market:  Switzerland
ISIN:  CH0012032113 
VALOR:  1203211
  • Volume: 50,074
  • Bid/Ask: 365.20 / 365.40
  • Day's Range: 361.80 - 366.00
Roche Holding 365.20 +1.60 +0.44%

RO Financial Summary

 
A brief financial summary of Roche Holding AG as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

For the fiscal year ended 31 December 2020, RocheHolding AG revenues decreased 5% to SF58.32B. Net incomeincreased 6% to SF14.3B. Revenues reflect United Statessegment decrease of 9% to SF27.19B, Latin America segmentdecrease of 16% to SF2.39B, Japan segment decrease of 9% toSF4.16B. Net income reflects Diagnostics segment incomeincrease from SF242M to SF2B, Corporate segment lossdecrease of 5% to SF610M.

AnnualQuarterly
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

RO Income Statement

Gross margin TTM 72.74%
Operating margin TTM 31.79%
Net Profit margin TTM 25.84%
Return on Investment TTM 26.63%
 Total Revenue  Net Income
Period Ending: Dec 31, 2020 Jun 30, 2020 Dec 31, 2019 Jun 30, 2019
Total Revenue 29042 29281 30997 30469
Gross Profit 20874 21549 22066 22023
Operating Income 7905 10638 6707 10841
Net Income 6216 8079 4878 8619

RO Balance Sheet

Quick Ratio MRQ 1.01
Current Ratio MRQ 1.3
LT Debt to Equity MRQ 28.12%
Total Debt to Equity MRQ 39.12%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2020 Jun 30, 2020 Dec 31, 2019 Jun 30, 2019
Total Assets 86138 80363 83091 80194
Total Liabilities 49797 48854 50344 52135
Total Equity 36341 31509 32747 28059

RO Cash Flow Statement

Cash Flow/Share TTM 22.69
Revenue/Share TTM 67.43
Operating Cash Flow  73.09%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2020 Jun 30, 2020 Dec 31, 2019 Jun 30, 2019
Period Length: 12 Months 6 Months 12 Months 6 Months
Cash From Operating Activities 18566 7062 22385 8115
Cash From Investing Activities -9067 -796 -8634 -1508
Cash From Financing Activities -9666 -8520 -14173 -7588
Net Change in Cash -348 -2305 -606 -992
* In Millions of CHF (except for per share items)
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

RO Comments

Write your thoughts about Roche Holding AG
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Sherlyn Jones
Sherlyn Jones Apr 22, 2021 6:47AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
A large pharmaceutical company, by the name of R. , is pushing down the value of the Spanish company's Pharmamar share price through the funds Consonance Capital and Great Point Partners, so that the biotech company accepts its offer of more than 4500 million dollars.According to this pharma, Pharmamar's products have a great future in oncology and virology, and would be fully engaged in its search for new drugs.
Reply
0 0
Report
Ruta Rublevska
Ruta Rublevska Nov 16, 2020 3:37AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
13.11.2020. CHMP recommends EU approval of Roche’s Xofluza® (baloxavir marboxil) for the treatment of influenza. This CHMP recommendation brings patients with influenza one step closer to potentially benefiting from Xofluza’s oral one-dose regimen, setting adults and adolescents on the path to feeling better sooner compared to placebo,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We believe that access to effective antivirals for influenza, and particularly their use in the prophylactic setting, could help reduce the strain of the COVID-19 pandemic on healthcare systems in Europe.
Reply
1 0
Report
Jonny Tr
Jonny Tr May 04, 2020 8:36AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Just like Biolidics. they get approval for Covid19 tests kits in USA
Reply
1 0
Report
Billy Hanafi
Billy Hanafi Jan 25, 2019 10:12AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
i dont know
Reply
0 0
Report
edgard hajjar
edgard hajjar May 07, 2018 5:38PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
is the historical price adjusted for stock splits?
Reply
2 0
Report
Billy Hanafi
Billy Hanafi May 07, 2018 5:38PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
i dont know
Reply
1 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email